Therapeutic choices in younger patients with chronic myelogenous leukemia

Cancer

Volumn 89, Issue 8, 2000, Pages 1647-1658

  Kantarjian, Hagop M ^a   Giles, Francis J ^a   O'Brien, Susan ^a   Giralt, Sergio ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic transplantation; Chronic myelogenous leukemia; Chronic myeloid leukemia; Interferon; Therapy; Treatment

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ARTICLE; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MYELOFIBROSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGE FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGE; MYELOFIBROSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034668122     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001015)89:8<1647::AID-CNCR1>3.0.CO;2-U     Document Type: Article

References (85)

1. Treatment of myelogenous leukemia: Current status and investigational options
2. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
3. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
4. Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation
5. Treatment of chronic myeloid leukemia by marrow transplantation
6. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
7. Bone marrow transplantation for chronic myelogenous leukemia
8. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
9. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
10. FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors
11. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): An update
12. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase
13. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
14. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
15. Marrow transplantation for CML: The Seattle experience
16. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2
17. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program
18. Randomized comparison of allogeneic bone marrow transplantation and interferon-based drug treatment in CML: Early results
19. Interferon alfa versus chemotherapy for chronic myeloid leukemia a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group
20. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
21. Chronic myelogenous leukemia - Progress at the M.D. Anderson Cancer Center over the past two decades and future directions: First Emil J Freireich Award Lecture
22. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia
23. A randomized trial comparing interferonalpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
24. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group
25. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia
26. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity
27. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
28. Unmaintained complete remissions (cures?) among interferon treated Philadelphia positive chronic myelogenous leukemia patients
29. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
30. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
31. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of Interferon-Alpha and low dose cytosine arabinoside
32. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: Results of a national prospective randomized trial
33. Simultaneous homoharringtonine and interferon alpha therapy is an effective regimen in Philadelphia chromosome positive chronic myelogenous leukemia in late chronic phase
34. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
35. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
36. Activity of an abl specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
37. Initial therapy for chronic myelogenous leukemia: Playing the odds
38. A chance of cure for every patient with chronic myeloid leukemia?
39. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
40. Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia
41. Cancer incidence and survival in patients 65 years of age and older
42. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period
43. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferonalpha
44. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group
45. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha
46. Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia an Italian Group for Bone Marrow Transplantation
47. Significant survival improvement with a combination of interferon alpha2b and cytarabine in chronic myelogenous leukemia. Update of a randomized trial
48. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
49. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
50. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
51. Tyrosine kinase inhibitors in chronic myeloid leukemia
52. Detection of minimal residual disease in all: Biology, methods, and applications
53. Can we cure indolent lymphomas?
54. Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined alltrans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
55. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
56. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
57. 1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry
58. Marrow transplantation for the treatment of chronic myelogenous leukemia
59. Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry
60. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the international bone marrow transplant registry
61. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits
62. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?
63. Characteristics of accelerated disease in chronic myelogenous leukemia
64. Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
65. IV busulfan, cyclophosphamide and allogeneic hemopoietic stem cells for chronic myeloid leukemia
66. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
67. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus
68. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program
69. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia
70. The relevance of reticulin stainmeasured fibrosis at diagnosis in chronic myelogenous leukemia
71. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy
72. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells
73. Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha
74. Treatment algorithm in CML: Bone marrow transplantation as frontline therapy
75. 'Sudden' blastic phase transformation in the first 2 years of interferon-a therapy for chronic phase chronic myelogenous leukemia
76. Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis
77. Survival after allogeneic bone marrow transplantation in patients randomized into a trial of IFN alpha versus chemotherapy: No significant adverse effect of prolonged IFN alpha administration
78. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia
79. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome
80. The adverse influence of pretransplant interferon-alpha (IFN-alpha) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure
81. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia
82. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for CML
83. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia
84. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure
85. Phase 1 study of pegylated-interferon alpha 2a (Pegasys) in patients with chronic myelogenous leukemia